Advanz Pharma UK
在场
Advanz Pharma UK 的所有者是 Advanz Pharma.
Advanz Pharma 是一家在股票代码 CXRXF (CA) 下上市的公司。
Advanz Pharma 在 2 个国家有直接业务。
高管
查看带有其 6 名主要高管的组织结构图
Advanz Pharma UK 搜索最多的简介
- Susanna El Armale, Chief Corporate Development Officer
- David McNamara, Vice President of Sourcing, Procurement and Suppli...
- Melvin Ferry, Finance Director
创建提醒
跟踪 Advanz Pharma UK 的高管变动
药店
Advanz Pharma 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
Advanz Pharma UK 的最新新闻稿
- ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe | ADVANZ PHARMA
- ADVANZ PHARMA acquires the rights to Nootropil® and Atarax® from UCB for Europe and selected countries in LATAM and APAC | ADVANZ PHARMA
- European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) | ADVANZ PHARMA
- ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2023-2024 | ADVANZ PHARMA
- ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) | ADVANZ PHARMA
- ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe | ADVANZ PHARMA
- ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation | ADVANZ PHARMA
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) | ADVANZ PHARMA
- ADVANZ PHARMA response to CHMP recommendation pertaining to EU conditional marketing authorization for OCALIVA® in rare disease Primary Biliary Cholangitis | ADVANZ PHARMA
- Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe | ADVANZ PHARMA
- View more press releases Close
通过电子邮件
